Sales & Marketing News | pharmaphorum

News

Could Novo-Catalent deal face antitrust hurdles?

Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings' purchase of Catalent and the sale of three manufacturing facilities

News

Novo Nordisk tackles supply issues with $11bn Catalent deal

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging

News

Astellas raises Padcev forecasts on bladder cancer data

Stellar results in a bladder cancer study have prompted Astellas to raise its peak sales prediction for Pfizer-partnered antibody-drug conjugate Padcev, although its new m

News

AbbVie’s new drugs keep post-Humira prospects on track

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in th

News

Hikma will pay $150m in US opioid settlement

Indian drugmaker Hikma has agreed in principle to a $150 million settlement to resolve lawsuits claiming that it contributed to the opioid crisis in the US, which could al

News

FDA sets date for Adaptimmune’s sarcoma drug verdict

The FDA is due to decide by 4th August whether to approve Adaptimmune’s engineered T-cell therapy for advanced synovial sarcoma, afamitresgene autoleucel (afami-cel), afte

Could Novo-Catalent deal face antitrust hurdles?

Novo Nordisk tackles supply issues with $11bn Catalent deal

Astellas raises Padcev forecasts on bladder cancer data

AbbVie’s new drugs keep post-Humira prospects on track

Hikma will pay $150m in US opioid settlement

FDA sets date for Adaptimmune’s sarcoma drug verdict

Making direct-to-patient work, with Matt Wadyka

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks